A5061645166- Virus-based gene therapy research
- Glioma Diagnosis and Treatment
- COVID-19 epidemiological studies
- Immune cells in cancer
- Computational Drug Discovery Methods
- Statistical Methods and Bayesian Inference
- PARP inhibition in cancer therapy
- Neuroblastoma Research and Treatments
- Data-Driven Disease Surveillance
- Single-cell and spatial transcriptomics
- CAR-T cell therapy research
- CRISPR and Genetic Engineering
- Control Systems and Identification
St. Jude Children's Research Hospital
2023-2025
University of Indianapolis
2021
Indiana University – Purdue University Indianapolis
2021
Shenyang 242 Hospital
2013
Exploratory analysis of single-cell RNA sequencing (scRNA-seq) typically relies on hard clustering over two-dimensional projections like uniform manifold approximation and projection (UMAP). However, such methods can severely distort the data have many arbitrary parameter choices. Methods that model scRNA-seq as non-discrete "gene expression programs" (GEPs) better preserve data's structure, but currently, they are often not scalable, consistent across repeated runs, lack an established...
Abstract Retinoic acid (RA) is a standard-of-care neuroblastoma drug thought to be effective by inducing differentiation. Curiously, RA has little effect on primary human tumors during upfront treatment but can eliminate cells from the bone marrow post-chemo maintenance therapy—a discrepancy that never been explained. To investigate this, we treat large cohort of cell lines with and observe most RA-sensitive predominantly undergo apoptosis or senescence, rather than We conduct genome-wide...
Combination chemotherapy is crucial for successfully treating cancer. However, the enormous number of possible drug combinations means discovering safe and effective remains a significant challenge. To improve this process, we conduct large-scale targeted CRISPR knockout screens in drug-treated cells, creating genetic map druggable genes that sensitize cells to commonly used chemotherapeutics. We prioritize neuroblastoma, most common extracranial pediatric solid tumor, where ~50% high-risk...